The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 25, 2022

Filed:

Jul. 24, 2019
Applicants:

Yuhan Corporation, Seoul, KR;

Industry-academic Cooperation Foundation, Yonsei University, Seoul, KR;

Inventors:

Moo Young Song, Gyeonggi-do, KR;

Taejin Yoon, Gyeonggi-do, KR;

Jung-Sun Lee, Seoul, KR;

Byung Hyun Choi, Gyeonggi-do, KR;

In Hwan Lim, Gyeonggi-do, KR;

Man Sil Park, Gyeonggi-do, KR;

Jin-Hyoung Lee, Gyeonggi-do, KR;

Hyoung Sig Seo, Gyeonggi-do, KR;

Hyeon Woo Kang, Gyeonggi-do, KR;

Sung Ho Kim, Seoul, KR;

Eun Jig Lee, Seoul, KR;

Jin Sook Yoon, Seoul, KR;

Cheol Ryong Ku, Seoul, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 47/68 (2017.01); C07K 14/72 (2006.01); C07K 19/00 (2006.01); A61K 47/64 (2017.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/72 (2013.01); A61K 38/1796 (2013.01); A61K 47/64 (2017.08); A61K 47/6811 (2017.08); A61K 38/00 (2013.01); C07K 2319/30 (2013.01);
Abstract

Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof. More specifically, disclosed are a fusion protein comprising a TSHR fragment comprising an extracellular domain of a wild-type TSHR and having a substitution of an amino acid at specific position and an immunoglobulin Fc region or a carboxy-terminal cap (C-CAP), and the use thereof. The fusion protein has improved pharmaceutical efficacy, in-vivo persistence and protein stability and a pharmaceutical composition containing the fusion protein as an active ingredient is useful as a therapeutic agent or diagnostic reagent for the alleviation of Graves' disease and Graves' ophthalmopathy.


Find Patent Forward Citations

Loading…